Menu
Back to Journals » Journal of Hepatocellular Carcinoma » Volume 8
Review
A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 13,705 | Dovepress* | 7,536+ | 1,106 | 8,642 | |
| PubMed Central* | 6,169 | 866 | 7,035 | ||
| Totals | 13,705 | 1,972 | 15,677 | ||
| *Since 15 April 2021 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 10 | 0 | 0 | 0 | 5 | 5 |
View citations on PubMed Central and Google Scholar